Find information on thousands of medical conditions and prescription drugs.

Velcade


Bortezomib (marketed as Velcade™ by Millenium Pharmaceuticals) is a "first-in-class" proteasome inhibitor. It is the best studied of a next generation of anti-myeloma drugs, and is also a potential treatment for plasma cell leukemia. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
Hydrocodone
Vagifem
Valaciclovir
Valcyte
Valganciclovir
Valine
Valium
Valnoctamide
Valproate semisodium
Valproic acid
Valpromide
Valrelease
Valsartan
Valstar
Valtrex
Vancenase
Vanceril
Vancomycin
Vaniqa
Vanticon
Vecuronium bromide
Velcade
Velivet
Venlafaxine
Ventolin
Vepesid
Verapamil
Verelan
Vermox
Versed
Vfend
Viadur
Viagra
Vicoprofen
Vidarabine
Vidaza
Videx
Vigabatrin
Viloxazine
Vinblastine
Vincristine
Vinorelbine
Viomycin
Vioxx
Viracept
Viread
Visine
Vistide
Visudyne
Vitaped
Vitrase
Vivelle
Volmax
Voltaren
Voriconazole
Vosol
W
X
Y
Z

Bortezomib works by blocking the action of 26S proteasome, which is a multicatalytic enzyme whose function is to degrade abnormal or misfolded proteins targeted for destruction. There is emerging evidence that 26S proteasome plays a role in myeloma and lymphoma.

The Multiple Myeloma Research Foundation was responsible for a substantial amount of the funding for the development and testing of this drug.

Side effects

Bortezomib is associated with peripheral neuropathy in 30% of patients; occasionally, it can be painful. This can be worse in patients with pre-existing neuropathy. In addition, myelosuppression as neutropenia and thrombocytopenia can also occur and be dose limiting.

Links

  • Millenium Pharmaceuticals website on Velcade™
  • International Myeloma Foundation article on Velcade™
  • US Food and Drugs Administration on Velcade™
  • Dedicated website for European audience

Read more at Wikipedia.org


[List your site here Free!]


New Data on VELCADE® for Injection to Be Presented at Upcoming American Society of Hematology Meeting
From PR Newswire, 12/6/05

-- Featured in 117 abstracts including 14 oral presentations and 72 posters --

CAMBRIDGE, Mass., Dec. 6 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. today announced that data from studies of VELCADE will be featured at the 47th Annual Meeting of the American Society of Hematology in Atlanta, GA., December 10-13, 2005.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

Highlights from clinical studies of VELCADE that will be presented include:

Abstracts can be accessed on the ASH website at http://www.hematology.org/ and were published in the November 16, 2005 issue of BLOOD, the journal of the American Society of Hematology.

About VELCADE

VELCADE is indicated for the treatment of multiple myeloma patients who have received at least one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy.

Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension, cardiac disorders, gastrointestinal adverse events, thrombocytopenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE.

In 331 patients who were treated with VELCADE in a phase III study, the most commonly reported adverse events were asthenic conditions (61%), diarrhea (57%), nausea (57%), constipation (42%), peripheral neuropathy (36%), vomiting (35%), pyrexia (35%), thrombocytopenia (35%), psychiatric disorders (35%), anorexia and appetite decreased (34%), parasthesia (27%), dysesthesia (27%), anemia and headache (26%), and cough (21%). Fourteen percent of patients reported at least one episode of grade 4 toxicity; the most common grade 4 toxicities were thrombocytopenia (4%), neutropenia (2%), and hypercalcemia (2%). A total of 144 patients on VELCADE (44%) reported serious adverse events (SAEs) during the study. The most commonly reported SAEs were pyrexia (6%), diarrhea (5%), dyspnea and pneumonia (4%), and vomiting (3%).

VELCADE is being co-developed by Millennium Pharmaceuticals, Inc. and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Millennium is responsible for commercialization of VELCADE in the U.S.; Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan. VELCADE is approved in more than 60 countries worldwide, including the U.S., the countries of the European Union and a number of countries within Latin America and South-East Asia. VELCADE is also approved in the European Union as a second-line treatment.

For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at 1-866-VELCADE (1-866-835-2233).

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. The Company's research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, its understanding of disease mechanisms and its industrialized drug discovery platform, Millennium is seeking to develop breakthrough products. The Company's website is http://www.millennium.com/.

Editor's Note: This release is available on the Media section of the Millennium website at http://www.millennium.com/.

CONTACT: Theresa McNeely, +1-617-679-7405, or Kyle Kuvalanka, +1-617-761-4734, both of Millennium Pharmaceuticals, Inc.

Web site: http://www.millennium.com/

Company News On-Call: http://www.prnewswire.com/comp/114562.html

COPYRIGHT 2005 PR Newswire Association LLC
COPYRIGHT 2005 Gale Group

Return to Velcade
Home Contact Resources Exchange Links ebay